RVNC - Revance Therapeutics Inc Stock Price, Fair Value and News

$3.79+0.06 (+1.61%)

Delayed as of 03 Dec 2024, 12:01 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

RVNC Price Action

Last 7 days

-1.8%

Last 30 days

-35.7%

Last 90 days

-43.4%

Trailing 12 Months

-48.5%

RVNC RSI Chart

RVNC Valuation

Market Cap

391.3M

Price/Earnings (Trailing)

-2.12

Price/Sales (Trailing)

1.56

Price/Free Cashflow

-2.01

RVNC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RVNC Fundamentals

RVNC Revenue

Revenue (TTM)

250.6M

Rev. Growth (Yr)

5.47%

Rev. Growth (Qtr)

-8.43%

RVNC Earnings

Earnings (TTM)

-184.4M

Earnings Growth (Yr)

73.02%

Earnings Growth (Qtr)

-1.6%

RVNC Profitability

Return on Equity

113.13%

Return on Assets

-39.96%

Free Cashflow Yield

-49.81%

RVNC Investor Care

Shares Dilution (1Y)

19.46%

Diluted EPS (TTM)

-1.95

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	236.6M	247.5M	250.6M	0
2023	153.1M	179.1M	206.9M	230.4M
2022	89.8M	99.3M	108.6M	132.6M
2021	28.6M	47.1M	63.0M	77.8M
2020	4.1M	7.9M	11.6M	15.3M
2019	4.3M	4.8M	5.1M	413.0K
2018	2.4M	3.1M	4.0M	3.7M
2017	1.2M	1.2M	963.0K	1.7M
2016	502.0K	777.0K	1.0M	1.2M
2015	252.0K	226.0K	219.0K	219.0K
2014	700.0K	700.0K	617.0K	383.0K
2013	266.8K	383.5K	500.3K	617.0K
2012	0	0	0	150.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Revance Therapeutics Inc

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

CEO	Mr. Mark J. Foley
WEBSITE	revance.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	534

Revance Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Revance Therapeutics Inc? What does RVNC stand for in stocks?

RVNC is the stock ticker symbol of Revance Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Revance Therapeutics Inc (RVNC)?

As of Mon Dec 02 2024, market cap of Revance Therapeutics Inc is 391.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RVNC stock?

You can check RVNC's fair value in chart for subscribers.

Is Revance Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RVNC is over valued or under valued. Whether Revance Therapeutics Inc is cheap or expensive depends on the assumptions which impact Revance Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RVNC.

What is Revance Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Dec 02 2024, RVNC's PE ratio (Price to Earnings) is -2.12 and Price to Sales (PS) ratio is 1.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RVNC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Revance Therapeutics Inc's stock?

In the past 10 years, Revance Therapeutics Inc has provided -0.142 (multiply by 100 for percentage) rate of return.